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Summary.-Our selection of a potential second-generation platinum compound
began with an initial short list of8 compounds selectedonthe basis of antitumour and
toxicity studies in mice. We now report further, more detailed investigations of the
renal toxicity and antitumour activity of one of these compounds, cis-dichloro
trans-dihydroxy bis isopropylamine platinum (IV) (CHIP), in comparison with
cis-dichloro diammine platinum (II) (Neoplatin). CHIP was a more effective anti-
tumour agent against both alkylating-agent sensitive and resistant strains of the
Yoshida sarcoma (YSs and YSR respectively) than was Neoplatin. In addition CHIP
produced negligible kidney toxicity as measured by blood urea levels.
We have also compared the effects of these two drugs on nuclear-protein phos-
phorylation, in an attempt to gain insight into their molecular mode of action. Both
Neoplatin and CHIP induced increased nuclear-protein phosphorylation in the YSs
tumour cells, and loss of condensed chromatin. However, CHIP also induced in-
creased nuclear-protein phosphorylation and loss of condensed chromatin in the YSR
tumour cells. These changes correlated well with cell death. In addition Neoplatin,
but not CHIP, treatment caused increased nuclear-protein phosphorylation in
kidney tissues. This correlated with kidney damage as measured by blood urea levels.
These selection criteria suggested that CHIP would be a more selective antitumour
agent than Neoplatin, and will provide a basis for its comparison with the other 7
compounds.
FOLLOWING EARLY REPORTS by Rosen-
berg et al. on the anti-bacterial effects of
the soluble salts of platinum (Rosenberg
et al., 1965, 1967) and, subsequently, on
the antitumour properties of cis-dichloro
diammine platinum (II) (Neoplatin)
(Rosenberg et al., 1969) extensive interest
has been generated in the chemical and
biological properties of platinum com-
plexes and of other heavy metals. This
has culminated in widespread clinical trials
of cis-dichloro diammine platinum (II)
(cisPt(II), Cisplatin, Neoplatin) mainly
against ovarian and testicular tumours
(Wiltshaw & Carr, 1974; Higby et al.,
1974; Wiltshaw & Kroner, 1976). Recent
clinical and experimental studies using
Neoplatin have been reviewed by Rosen-
cweig et al. (1977) and Prestayko et al.
(1979).
Unfortunately, toxic side effects may
restrict the clinical utility of Neoplatin.
The toxic effects are mainly nephrotoxicity
and nausea and vomiting, but neuro-
toxicity and myelosuppression have also
been reported (Wiltshaw & Carr, 1974;
Hill et al., 1974; Wallace & Higby, 1974;
Kraurs et al., 1979). Nausea and vomiting
have frequently been of sufficient severity
to cause the patient to refuse further
treatment (Kane et al., 1978). Without
hydration or osmotic diuresis, relatively
* To whom all correspondence should be addressedl.
t Ludwig Hirszfeld Institute of Immtunology and Experimental Thlerapy, Polish Academy of Sciences,
Warsaw, Poland.SECOND GENERATION PLATINUM COMPOUNDS
low doses of Neoplatin produced dose-
limiting toxicities (Randoph & Wittes,
1978) and forced diuresis or manitol
hydration are now used routinely (Hayes
et al., 1.977; Prestayko et al., 1979).
Cumulative toxicity, however, can still
limit the clinical use ofNeoplatin (Dentino
et al., 1978; Gonzalez-Vitale, 1977).
Since 1970, some 300 derivatives of cis-
dichloro diammine platinum (II) have
been assessed for antitumour activity by
the Institute of Cancer Research (Connors
et al., 1972; Braddock et al., 1975). Many
others have been screened at other centres
throughout the world (Cleare et al., 1978).
From these data, we selected 8 compounds
for further preclinical evaluation (Wilkin-
son et al., 1978).
In the present communication we report
the antitumour properties and cellular
activity of one of the compounds, cis-
dichloro trans-dihydroxy bis isopropyl-
amine platinum (IV) (CHIP) in compari-
son with Neoplatin. Measurement of blood
urea and urinary protein levels have pro-
vided an indication of kidney toxicity. We
have compared antitumour activity in a
Yoshida sarcoma tumour line sensitive to
alkylating agents (YSs), withthatachieved
using a line exhibiting acquired resistance
to alkylating agents (YSR) (Harrap &
Furness, 1973).
Neoplatin has some properties in com-
mon with bifunctional alkylating agents,
particularly with respect to its ability to
bind and cross-link DNA (Roberts &
Pascoe, 1972; Zwelling et al., 1978). The
biochemical effects of various platinum
complexes on DNA and DNA repair have
been recently reviewed by Roberts &
Thomson (1979). We have previously
shown that chlorambucil, melphalan and
cyclophosphamide, in addition to cross-
linking DNA, also induce an increase in
nuclear-protein phosphorylation, accom-
panied by a loss of condensed chromatin
in YSs cells (Wilkinson et al., 1979). These
changes have been directly correlated
with toxicity, and appear to play a major
role in determining cell death following
bifunctional alkylating-agent treatment.
We have now investigated the possibility
that platinum compounds may also induce
similar changes in nuclear-protein phos-
phorylation and nuclear morphology.
MATERIALS AND METHODS
Both Neoplatin and CHIP were generous
gifts from the Johnson Matthey Research
Centre (Blount's Court, Sonning Common,
Bucks, England). Adenosine 5'-(y-32P)tri-
phosphate was purchased from the Radio-
chemical Centre (Amersham, Bucks). All
other reagents were obtained from Hopkin
and Williams Ltd, Chadwell Heath, Essex,
or British Drug Houses Ltd, Poole, Dorset.
Analytical grades were used whenever avail-
able.
Assessment of kidney toxicity.-Blood-urea
studies were conducted using groups of 10
normal female Wistar rats. Drugs were
administered by i.p. injection in 0-9% NaCl
solution. All animals were bled from the tail
vein using heparinized Pasteur pipettes, and
the blood placed in previously heparinized
microfuge tubes containing 10 pul of heparin
(1000 i.u./ml). The blood was microfuged for 5
min to produce 200 ,ul ofplasma which was
storedat4°C. Theplasma was defibrinated and
the urea level determined in a Technics Mk 2
auto-analyser as previously described (Marsh
et al., 1963). All rats were weighed daily and
the group average calculated.
Urinary protein was assayed daily using
Ames Labstix on groups of 3 rats maintained
in metabolism cages.
Antitumour activity.-Toxicity of both
platinum drugswasdeterminedusinglogarith-
mically spaced (2-fold) dose levels as pre-
viously described (Rosenoer et al., 1966).
The ability of Neoplatin and CHIP to
inhibit the growth of the Yoshida ascites
sarcoma in female Wistar rats was deter-
mined as previously described (Harrap & Hill,
1969). Briefly, animals bearing a tumour load
of 108 cells which were either sensitive to
alkylating-agent toxicity, or had a 50-fold
acquired resistance to a wide range ofalkylat-
ing agents (Harrap & Furness, 1973) were
injected s.c. with various doses of either
Neoplatin or CHIP dissolved in DMSO. The
surviving tumour cells were counted for the
subsequent 3 days.
Nuclear-profein phosphorylation. -Nuclei
were prepared as previously described (Rick-
wood et al., 1973) and nuclear-protein phos-
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phorylation was measured in tumour-cell
nuclei and kidney and liver-cell nuclei at 24,
48 and 72 h after treatment oftumour-bearing
rats. Phosphorylation was determined bythe
ability of isolated nuclei to incorporate
[y-32P]-ATP into total nuclear proteins
(Rickwood et al., 1973).
Nuclear morphology.-48 h after treatment
of tumour-bearing rats, ascites cells were
removed from the peritoneal cavity, fixed in
gluteraldehyde cacodylate buffer, post-fixed
in osmium tetroxide and embedded in Aral-
dite. Ultra-thin sections were stained in an
alkaline lead solution before being examined
under an electron microscope (Kornovsky,
1961).
RESULTS
For the toxicological studies described
in Figs 1 and 2, both drugs were adminis-
tered at doses equivalent to 80% of the
calculated LD50.
Fig. 1 summarizes the blood urea,
urinary protein and total body-wt changes
after treatment with Neoplatin at 8 mg/
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FiG. 1. Toxicity study of Neoplatin: 10
female Wistar rats received 8 mg/kg
Neoplatin dissolved in saline i.p. Animals
were weighed each day and blood urea
(5 rats) and urinary protein (3 rats) meas-
ured as described in Materials and Methods.
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FIa. 2. Toxicity study of CHIP: 10 female
Wistar rats received 48 mg/kg CHIP dis-
solved in saline i.p. Animals were weighed
each day and blood urea (5 rats) and urin-
ary protein (3 rats) measured as described
in Materials and Methods.
Blood urea rose to 19 times that of the
resting level, while urinary protein rose to
the maximum on the scale. The animals
also lost 23% oftheir initial body wt. It is
ofinterest to note that both diarrhoea and
anaemia were encountered in a manner
similar to that seen after whole-body
irradiation (Lamerton et at., 1953). CHIP
at 48 mg/kg, however, exhibited a differ-
ent spectrum oftoxicity, with no lethality,
as seen in Fig. 2. After an initial weight
loss, recovery was rapid with only mild
diarrhoea during this phase. The blood-
urea curve for CHIP showed little change
from resting level, reaching a peak on the
eleventh day after treatment (64% in-
crease).
Antitumour effect
For antitumour studies, Neoplatin and
CHIP were administered s.c. at their
maximum tolerated dose levels, 15 mg/kg
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FIG. 3. Antitumour effect of Neoplatin:
Groups of 10 female Wistar rats were in-
jected i.p., wvitli either sensitive or resistant
Yoslidla sarcoma cells on Day - 3. Neo-
platin, (lissolvedl in DAISO, was injected
s.c. at a dose of 15 mg/kg on Day 0. Viable
tumour cells were couinted each day for the
next 3 days. O, sensitive control; -, sensi-
tix e Neoplatin; 0, resistant conitrol;
*, resistant Neoplatin. Data are thie means





FIG. 4. Antitumour effect of CHIP: Groups
of 10 female Wistar rats were injected i.p.
with either sensitive or resistant Yoshicla
sarcoma cellsonDay - 3. CHIP, dissolved in
DMSO, was injected s.c. atadoseof80mg/kg
on Day 0. Viable tumour cells were counted
eacli day for the next 3 days. 0, sensitiVe
control; A, sensitive CHIP; *, resistant
control; *, resistant CHIP. Data are the
means + s.e. of 3 determinations.
caused no deaths or sustained weight loss
to non-tumour-bearing rats (LD5o 45 mg/
kg and 92 mg/kg for Neoplatin and CHIP
respectively).
Although the sensitive strain of the
Yoshida sarcoma is cured with a single s.c.
dose of 8 mg/kg of chlorambucil (Harrap
& Hill, 1969) Neoplatin produced only
minimal inhibition of growth, and there
was little difference between the response
of the sensitive and resistant strains
(Fig. 3). After CHIP treatment the sensi-
tive tumour failed to regrow within 10
days of drug treatment, and was con-
sidered to have been "cured". Treatment
72 of the YSR tumour with the same dose of
CHIP produced a 70%O inhibition of cell
growth at 72 h compared with control
cells (Fig. 4). Thus it is apparent that
CHIP exerts markedly greater effects
against the sensitive tumour than can be
achieved with Neoplatin. On the other
hand the activity of both compounds







FIG. 5. Phosphorylation of nuclear protein
in Yoshida sarcoma: Rats bearing the
Yosliida ascites sarcoma received 15 mg/kg
Neoplatin, dissolved in DMSO, s.c. on Day
0. The ability of isolated nuclei to incor-
porate [y-32P]-ATP into nuclear protein
was measured at various times after treat-
ment. Data are the means + s.e. of 3 deter-
minations. 0, sensitive Yoshida; *, re-
sistant, Yoshida.
72










FIG. 6. Phosphorylation of nuclear protein
in Yoshida sarcoma: Rats bearing the
Yoshida ascites sarcoma received 80mg/kg
CHIP, dissolved in DMSO, s.c. on Day 0.
The ability ofisolated nuclei to incorporate
[y_32P]-ATP into nuclear proteins was
measured at various times after treatment.
Data.are the means+s.e. of 3 determina-
tions. 0, sensitive Yoshida; *, resistant
Yoshida.
Nuclear-proteinphosphorylation
Fig. 5 shows the pattern of nuclear-
protein phosphorylation in both strains of
the Yoshida sarcoma after treatment of
tumour-bearing rats with Neoplatin.
Nuclear-protein phosphorylation was
stimulated in the YSS cells but not in the
YSR cells. Fig. 6 shows the pattern of
nuclear-protein phosphorylation following
CHIP treatment. Increases were seen in
both strains, though the extent of phos-
phorylation was greater in the YSS cells,
correlating with their enhanced cell kill.
We also measured nuclear-protein phos-
phorylation in kidney tissues. Our aim
was to determine whether phosphoryla-
tion in the kidney could be correlated with
nephrotoxicity. As seen in Fig. 7, Neo-
platin stimulated nuclear-protein phos-
phorylation in kidney tissues but CHIP
did not. This difference is highly signifi-
cant and correlated wellwith the increased






FIG. 7. Nuclear-protein phosphorylation in
kidney: Tumour-bearing rats received 15
mg/kg Neoplatin or 80 mg/kg CHIP s.c. on
Day 0. On subsequent days kidneys were
removed and the ability of isolated nuclei
to incorporate [y-32P]-ATP into nucjlear
protein was measured. Data are the means
+s.e. of 3 determinations. *, Neoplatin;
0, CHIP.
Neoplatin. Neither Neoplatin nor CHIP
induced large increases in the nuclear-
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* Control 25,000 ct/min [y-32P]-ATP/mg DNA!
5 min.
t Time after drug treatment of tumour-bearing
rats.
Nuclear morphology
Sensitive and resistant Yoshida cells
exhibit identical morphology under the
electron microscope. Fig. 8 is an electron
micrograph of an untreated resistant cell.
In addition to 2 nucleolar areas, there are
other regions of condensed chromatin
within the body ofthe nucleus and around
the nuclear membrane. No morphological
changes were seen in nuclei of resistant
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FIG. 8.-Electron micrograph of a nucleus of a control Yoshida sarcoma cell resistant to alkylating
agents. x 15,000.
FIG. 9.-Electron micrograph of a nucleus of a Yoshida sarcoma cell sensitive to alkylating agents
48 h after treatment of tumour-bearing rats with Neoplatin at 15 mg/kg. x 15,000.
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FiG. 10. Electron micrograph of a nucleus of a Yoshida sarcoma cell resistant to alkylating agents
48 h after treatment of tumour-bearing rats with CHIP at 80 mg/kg. x 15,000.
tumour cells after Neoplatin though in
sensitive cells the condensed chromatin
was lost, with no significant change to the
nucleolus. Fig. 9 shows a sensitive cell 48 h
after Neoplatin treatment of a tumour-
bearing rat. The effects are reminiscent of
those seen after alkylating agent treat-
ment of Wistar rats bearing the sensitive
tumour (Wilkinson et al., 1979). After
treatment of tumour-bearing rats with
CHIP, there was a total loss of condensed
chromatin in both the sensitive and re-
sistant tumour cells (Fig. 10). This figure
shows a resistant tumour cell 48 h after
CHIP treatment of tumour-bearing rats.
There is a total loss of condensed chrom-
atin within the body of the nucleus and
around the nuclear membrane.
DISCUSSION
Our data indicate that CHIP has far
less host toxicity as measured by body-wt
loss, increased blood urea, or urinary
protein and chromatin damage, than does
Neoplatin, when both are'administered at
maximum tolerated levels. The anti-
tumour effects against a spectrum of
transplantable rodent tumours indicate
that CHIP has an antitumour effect equal
to, or greater than, that of Neoplatin
(Cleare et al., 1978). Whilst the clinical
efficacy of Neoplatin against a number of
human tumours has been demonstrated,
its unpleasant side effects necessitate the
introduction of a less toxic congener into
clinical use. Our current studies would
indicate that CHIP is a more selective
cis-platinum congener, and is worthy of
consideration as an alternative platinum
drug. However, more detailed preclinical
studies would be required before final
evaluation is possible.
Our previous studies on the mode of
action of bifunctional alkylating agents
have indicated that increased nuclear-
protein phosphorylation is an essential
prerequisite for DNA damage. Unless
nuclear-protein phosphorylation increases,
the subsequent cross-linking of DNA does
not cause cell death (Wilkinson et al.,
1979). Platinum drugs, in particular Neo-
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platin, also cross-link DNA (Roberts &
Thomson, 1979; Zwelling et al., 1978) and
our present studies describe increased
nuclear-protein phosphorylation after
Neoplatin and CHIP. These changes are
equivalent to those seen after bifunctional
alkylating agents, and they correlate
directly with the selective cell and tissue
damage observed.
The chromatin aberrations observed
also correlate well with modifications to
nuclear morphology in tumour tissues.
The condensed nuclear material is lost in
tissues exhibiting drug damage. Similar
morphological changes have also been
found after Neoplatin treatment of Sar-
coma 180 (Sodhi, 1977). These modifica-
tions to chromatin material by platinum
drugs are reminiscent of those induced by
bifunctional alkylating agents (Wilkinson
et al., 1979) and indicate further simi-
larities in their molecular modes of action.
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